膜杰作
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax
> 【VEGF-B】
VEGF-B信息
英文名称：Vascular endothelial growth factor B
中文名称：血管内皮生长因子B
靶点别称：VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
中文名称：血管内皮生长因子B
靶点别称：VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
上市药物数量：1
临床药物数量：2
最高研发阶段：批准上市
临床药物数量：2
最高研发阶段：批准上市
VEGF-B 分子别名
VRF,VEGFL,VEGFB,VEGF-B
VEGF-B 分子背景
Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.
VEGF-B 前沿进展
VEGF-B上市药物信息
| 英文名称 | 中文名称 | 研发代码 | 研发阶段 | 公司 | 最早商品名 | 最早批准国家 | 最早适应症 | 最早批准公司 | 最早批准日期 | 适应症 | 临床试验 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ziv-aflibercept | BAY-865321; AVE-0005 | 批准上市 | Regeneron Pharmaceuticals Inc, 赛诺菲 | Zaltrap | Japan | 结直肠癌 | Sanofi | 2012-08-03 | 卵巢癌, 实体瘤, 腹水, 肺疾病, 前列腺癌, 结直肠癌, 肺癌, 淋巴瘤, 转移癌 | 详情 |
VEGF-B临床药物信息
| 英文名称 | 研发代码 | 研发阶段 | 公司 | 适应症 | 临床试验 |
|---|---|---|---|---|---|
| CSL-346 | 2H-10; CSL-346 | 临床二期 | Csl Ltd | 二型糖尿病, 糖尿病肾病 | 详情 |
